Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies

Author(s): Flossmann E, Rothwell PM; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial

Abstract

Background: Randomised trials have shown that aspirin reduces the short-term risk of recurrent colorectal adenomas in patients with a history of adenomas or cancer, but large trials have shown no effect in primary prevention of colorectal cancer during 10 years' follow-up. However, the delay from the early development of adenoma to presentation with cancer is at least 10 years. We aimed to assess the longer-term effect of aspirin on the incidence of cancers.

Methods: We studied the effect of aspirin in two large randomised trials with reliable post-trial follow-up for more than 20 years: the British Doctors Aspirin Trial (N=5139, two-thirds allocated 500 mg aspirin for 5 years, a third to open control) and UK-TIA Aspirin Trial (N=2449, two-thirds allocated 300 mg or 1200 mg aspirin for 1-7 years, a third placebo control). We also did a systematic review of all relevant observational studies to establish whether associations were consistent with the results of the randomised trials and, if so, what could be concluded about the likely effects of dose and regularity of aspirin use, other non-steroidal anti-inflammatory drugs (NSAID), and the effect of patient characteristics.

Results: In the randomised trials, allocation to aspirin reduced the incidence of colorectal cancer (pooled HR 0.74, 95% CI 0.56-0.97, p=0.02 overall; 0.63, 0.47-0.85, p=0.002 if allocated aspirin for 5 years or more). However, this effect was only seen after a latency of 10 years (years 0-9: 0.92, 0.56-1.49, p=0.73; years 10-19: 0.60, 0.42-0.87, p=0.007), was dependent on duration of scheduled trial treatment and compliance, and was greatest 10-14 years after randomisation in patients who had had scheduled trial treatment of 5 years or more (0.37, 0.20-0.70, p=0.002; 0.26, 0.12-0.56, p=0.0002, if compliant). No significant effect on incidence of non-colorectal cancers was recorded (1.01, 0.88-1.16, p=0.87). In 19 case-control studies (20 815 cases) and 11 cohort studies (1 136 110 individuals), regular use of aspirin or NSAID was consistently associated with a reduced risk of colorectal cancer, especially after use for 10 years or more, with no difference between aspirin and other NSAIDs, or in relation to age, sex, race, or family history, site or aggressiveness of cancer, or any reduction in apparent effect with use for 20 years or more. However, a consistent association was only seen with use of 300 mg or more of aspirin a day, with diminished and inconsistent results for lower or less frequent doses.

Interpretation: Use of 300 mg or more of aspirin a day for about 5 years is effective in primary prevention of colorectal cancer in randomised controlled trials, with a latency of about 10 years, which is consistent with findings from observational studies. Long-term follow-up is required from other randomised trials to establish the effects of lower or less frequent doses of aspirin.

Similar Articles

Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality

Author(s): Chang Y, Schechter CB, van Ravesteyn NT, Near AM, Heijnsdijk EA, et al.

Cost-effectiveness of screening for colorectal cancer in the general population

Author(s): Frazier AL, Colditz GA, Fuchs CS, Kuntz KM

50-year trends in smoking-related mortality in the United States

Author(s): Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, et al.

Body-mass index and mortality in a prospective cohort of U

Author(s): Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr

Weight Control and Physical Activity

Author(s): Vainio H, Kaaks R, Bianchini F

Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer

Author(s): Smith-Warner SA, Spiegelman D, Ritz J, Albanes D, Beeson WL, et al.

Alcohol consumption and mortality among middle-aged and elderly U

Author(s): Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ, et al.

Aspirin use and reduced risk of fatal colon cancer

Author(s): Thun MJ, Namboodiri MM, Heath CW Jr

A randomized trial of aspirin to prevent colorectal adenomas

Author(s): Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, et al.

Aspirin and the risk of colorectal cancer in women

Author(s): Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, et al.

Breast cancer and hormone replacement therapy

Author(s): [No authors listed]

A candidate gene approach to searching for low-penetrance breast and prostate cancer genes

Author(s): Hunter DJ, Riboli E, Haiman CA, Albanes D, Altshuler D, et al.

Identification of a new prostate cancer susceptibility locus on chromosome 8q24

Author(s): Yeager M, Chatterjee N, Ciampa J, Jacobs KB, Gonzalez-Bosquet J, et al.

Body-mass index and mortality among 1

Author(s): Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, et al.

Following cancer prevention guidelines reduces risk of cancer, cardiovascular disease, and all-cause mortality

Author(s): McCullough ML, Patel AV, Kushi LH, Patel R, Willett WC, et al.

Transforming epidemiology for 21st century medicine and public health

Author(s): Khoury MJ, Lam TK, Ioannidis JP, Hartge P, Spitz MR, et al.

The economic costs of non-insulin-dependent diabetes mellitus

Author(s): Huse DM, Oster G, Killen AR, Lacey MJ, Colditz GA

Prevention of venous thromboembolism after general surgery

Author(s): Oster G, Tuden RL, Colditz GA

Cost-effectiveness of cervical-cancer screening in five developing countries

Author(s): Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, et al.